Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation

Trial Profile

Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms IMPemBra
  • Most Recent Events

    • 14 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top